First BCMA CAR T-Cell Therapy Approved for Multiple Myeloma
The U.S. Food and Drug Administration (FDA) approved idecabtagene vicleucel (ide-cel) for the treatment of adults with relapsed/refractory multiple myeloma (RRMM) following four or more previous treatments, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody. Ide-cel is the first B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapy to be approved for this disease.